
B/m/vinci8/data1/riedel/corpora/nyt/nyt/data/2006/03/28/1750178.xmlö


ADTO

widelyRBO

usedVBNO

drugNNO

thatWDTO

hasVBZO

beenVBNO

miredVBNO

inINO

controversyNNO

forINO

mostJJSO

ofINO

itsPRP$O

decade-longJJO

lifeNNO

mayMDO

nowRBO

bringVBO

reliefNNO

toTOO

postmenopausalJJO

womenNNSO

whoseWP$O

livesNNSO

haveVBPO

beenVBNO

	disruptedVBNO

byINO

unrelentingVBGO

hotJJO

flashesNNSO
	
..O•

TheDTO

reliefNNO

mayMDO

beVBO


especiallyRBO

welcomeJJO

toTOO

womenNNSO

whoWPO

haveVBPO

hadVBNO

breastNNO

cancerNNO

andCCO

canMDO

notRBO

takeVBO

estrogenNNO
	
..Oß

TheDTO

drugNNO
	
,,O

bestRBO

knownVBNO

byINO

itsPRP$O

tradeNNO

nameNNO
	
,,O

	NeurontinNNPPERSON
	
,,O

butCCO

nowRBO


prescribedVBNO

genericallyRBO

asINO


gabapentinNNO
	
,,O

wasVBDO

approvedVBNO

byINO

theDTO

FoodNNPORGANIZATION

andCCORGANIZATION

DrugNNPORGANIZATION
#
AdministrationNNPORGANIZATION

inINO

1994CDO

toTOO

treatVBO

	epilepticJJO

seizuresNNSO
	
..OEÇÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f8000000000018a7c *ORGANIZATIONÉÄÄÄ¯ˇˇˇˇ
 
*PERSON£

InINO

2002CDO
	
,,O

itPRPO

wasVBDO

approvedVBNO

toTOO

treatVBO

postherpeticJJO

	neuralgiaNNO
	
,,O

horrificJJO

painNNO

thatWDTO

	sometimesRBO

followsVBZO

shinglesNNSO
	
..O‘

AidedVBNO

byINO

theDTO

InternetNNPO

andCCO
	
,,O

theDTO


governmentNNO

hasVBZO

saidVBNO
	
,,O

anDTO

illegalJJO

	marketingNNO

campaignNNO

byINO

itsPRP$O

parentNNO

companyNNO
	
,,O

	NeurontinRBORGANIZATION

salesNNSO


eventuallyRBO

exceededVBDO
	
$$O


2CDO

billionCDO


aDTO

yearNNO

beforeINO

itsPRP$O

patentNNO

expiredVBDO

andCCO

theDTO

genericJJO


gabapentinNNO

enteredVBDO

theDTO

marketNNO

inINO

2004CDO
	
..OÑÄÄÄ¯ˇˇˇˇ *ORGANIZATION

TheDTO

parentNNO

companyNNO
	
,,O
#
Warner-LambertNNPORGANIZATION

-LRB--LRB-O

sinceINO

boughtVBNO

byINO

PfizerNNPO

-RRB--RRB-O
	
,,O

wasVBDO

investigatedVBNO

afterINO


aDTO

whistle-blowerNNO

saidVBDO

itPRPO

hadVBDO

paidVBNO

doctorsNNSO

toTOO

promoteVBO

	NeurontinNNPPERSON

toTOO

theirPRP$O


colleaguesNNSO

forINO


aDTO

hostNNO

ofINO


additionalJJO

symptomsNNSO

notRBO

approvedVBNO

byINO

theDTO

F.D.A.NNPORGANIZATION

TheDTO

whistle-blowerNNO

alsoRBO

saidVBDO

theDTO

companyNNO

hadVBDO

paidVBNO

toTOO

haveVBO

researchNNO

articlesNNSO

preparedVBNO

claimingVBGO

benefitsNNSO

ofINO


aDTO

dubiousJJO

natureNNO
	
..OÖÄÄÄ¯ˇˇˇˇ& &*ORGANIZATIONÜÄÄÄ¯ˇˇˇˇ *PERSONEáÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f8000000008c0b2d8 *ORGANIZATION“

VariedJJO

ApplicationsNNSO

AsINO


aDTO

resultNNO
	
,,O

	NeurontinNNPPERSON

hasVBZO

beenVBNO

usedVBNO

forINO

problemsNNSO

likeINO

	migrainesNNSO
	
,,O

socialJJO

phobiaNNO
	
,,O

attention-deficitNNO

disorderNNO

inINO

childrenNNSO
	
,,O

gastricJJO

ulcersNNSO
	
,,O

restlessJJO

legNNO

syndromeNNO
	
,,O

	essentialJJO

tremorNNO
	
,,O

osteoarthritisNNO
	
,,O

backacheNNO
	
,,O

insomniaNNO
	
,,O

anxietyNNO
	
,,O

bipolarJJO

disorderNNO
	
,,O

panicNNO

attacksNNSO

andCCO


withdrawalNNO

fromINO

cocaineNNO

andCCO

alcoholNNO


--:O

allDTO

knownVBNO

asINO

	off-labelJJO

usesNNSO
	
..OàÄÄÄ¯ˇˇˇˇ *PERSON¯

ItsPRP$O

mostRBSO

frequentJJO

	off-labelJJO

useNNO

isVBZO

asINO

anDTO

adjunctJJO

toTOO

drugsNNSO

usedVBNO

toTOO

treatVBO

painNNO
	
,,O


especiallyRBO

painNNO

thoughtVBDO

toTOO

haveVBO

nerveNNO

involvementNNO
	
..O⁄

ThusRBO
	
,,O


gabapentinNNO

wasVBDO

partNNO

ofINO

theDTO


medicationNNO


prescribedVBNO

forINO

myPRP$O

unrelentingJJO

painNNO

afterINO


aDTO

doubleJJO

knee-replacementNNO

	operationNNO

lastJJO

yearNNO
	
..OË

ItPRPO

wasVBDO


prescribedVBNO

againRBO

lastJJO

fallNNO

whenWRBO

IPRPO

	developedVBDO

debilitatingVBGO

backRBO

andCCO

legNNO

painNNO

causedVBNO

byINO


aDTO

pinchedJJO

nerveNNO

inINO

myPRP$O

backNNO
	
..Oà

BetweenINO

theDTO

twoCDO

prescriptionsNNSO
	
,,O

IPRPO

madeVBDO


aDTO

	discoveryNNO

thatINO

changedVBDO

myPRP$O

lifeNNO

forINO

theDTO

betterJJRO
	
..O⁄

WhileINO

takingVBGO

	NeurontinRBPERSON

threeCDO

timesNNSO


aDTO

dayNNO

forINO

theDTO

kneeNNO

painNNO
	
,,O

IPRPO

hadVBDO

noneNNO

ofINO

theDTO

hotJJO

flashesNNSO

thatWDTO

hadVBDO

plaguedVBNO

mePRPO

dayNNO

andCCO

nightNNO

afterINO

breastNNO

cancerNNO

inINO

1999CDO

madeVBDO

mePRPO

stopVBO

postmenopausalJJO

hormonesNNSO
	
..OâÄÄÄ¯ˇˇˇˇ *PERSONÙ

ButCCO

whenWRBO

IPRPO

weanedVBDO

myselfPRPO

fromINO


gabapentinNNO

lastJJO

MayNNPO
	
,,O

theDTO

hotJJO

flashesNNSO

returnedVBNO
	
,,O

	resultingVBGO

inINO

threeCDO

	sleeplessJJO

nightsNNSO

inINO


aDTO

rowNNO
	
..Oí

IPRPO

wonderedVBDO

whetherINO

itPRPO

couldMDO

beVBO


aDTO

factorNNO

andCCO

decidedVBDO
	
,,O

withINO

myPRP$O

doctorNNO

'sPOSO

approvalNNO
	
,,O

toTOO

tryVBO

justRBO

oneCDO

300-milligramJJO

capsuleNNO

beforeINO

bedtimeNNO
	
..O

Voil√†NNPO
	
!.O9

NoDTO

hotJJO

flashesNNSO
	
..O 

NoDTO

wakingVBGO

upINO

dampJJO

andCCO

clammyJJO

andCCO

unableJJO

toTOO

goVBO

backRBO

toTOO

sleepVBO
	
..Oä

IPRPO

'veVBPO

stayedVBNO

onINO

theDTO

drugNNO
	
,,O

andCCO

thisDTO

winterNNO

IPRPO

'veVBPO

beenVBNO

ableJJO

toTOO

wearVBO

turtlenecksNNSO
	
..O[

IPRPO

'mVBPO

sleepingVBGO

muchRBO

betterJJRO
	
..Oø

OnINO

theDTO

doseNNO

thatWDTO

helpsVBZO

mePRPO


--:O

300CDO


milligramsNNSO

afterINO

	breakfastNNO

andCCO

300CDO

orCCO

600CDO


milligramsNNSO

atINO

bedtimeNNO


--:O

IPRPO

'veVBPO

noticedVBNO

noDTO

unusualJJO

effectsNNSO

beyondINO

anDTO

abilityNNO

toTOO

sleepVBO

comfortablyRBO

forINO

sevenCDO

hoursNNSO


aDTO

nightNNO
	
..O‘

LastJJO

	SeptemberNNPO
	
,,O

IPRPO

foundVBDO


aDTO

reportNNO

inINO

TheDTO

LancetNNPO
	
,,O

theDTO

medicalJJO

journalNNO
	
,,O

byINO

researchersNNSO

fromINO

fourCDO

medicalJJO

centersNNSO

whoWPO

	conductedVBDO


aDTO

clinicNNO

trialNNO

usingVBGO


gabapentinNNO

toTOO

treatVBO

hotJJO

flashesNNSO

inINO

womenNNSO

withINO

breastNNO

cancerNNO
	
..Oÿ

InINO

theDTO

studyNNO
	
,,O

420CDO

womenNNSO

havingVBGO

twoCDO

orCCO

moreJJRO

hotJJO

flashesNNSO


aDTO

dayNNO

wereVBDO

randomlyRBO

assignedVBNO

toTOO

takeVBO

300CDO

orCCO

900CDO


milligramsNNSO

ofINO


gabapentinNNO

orCCO


aDTO


look-alikeJJO

placeboNNO

eachDTO

dayNNO

inINO

threeCDO

dividedJJO

dosesNNSO

forINO

eightCDO

weeksNNSO
	
..OÕ

AboutINO

oneCDO

patientNNO

inINO

fiveCDO

onINO

theDTO

placeboNNO

reportedVBDO


aDTO

declineNNO

inINO

hotJJO

flashesNNSO
	
,,O

whileINO


aDTO

thirdJJO

ofINO

thoseDTO

takingVBGO

300CDO


milligramsNNSO

ofINO


gabapentinNNO

didVBDO

andCCO

nearlyRBO

halfNNO

ofINO

thoseDTO

onINO

900CDO


milligramsNNSO

reportedVBDO


aDTO

benefitNNO
	
..Oè

TheDTO

researchersNNSO
	
,,O

ledVBNO

byINO

Dr.NNPPERSON

KishanNNPPERSON

J.NNPPERSON

PandyaNNPPERSON

ofINO

theDTO

JamesNNPPERSON

P.NNPPERSON

WilmotNNPPERSON

CancerNNPO

CenterNNPO

atINO

theDTO


UniversityNNPORGANIZATION

ofINORGANIZATION

	RochesterNNPORGANIZATION

MedicalNNPORGANIZATION

CenterNNPORGANIZATION
	
,,O

foundVBDO

thatDTO

''''O

onlyRBO

theDTO

higherJJRO

doseNNO

ofINO


gabapentinNNO

wasVBDO


associatedVBNO

withINO

significantJJO

	decreasesNNSO

inINO

hotJJO

flashNNO

	frequencyNNO

andCCO

severityNNO
	
..O

''''OäÄÄÄ¯ˇˇˇˇ *ORGANIZATIONãÄÄÄ¯ˇˇˇˇ *PERSONåÄÄÄ¯ˇˇˇˇ *PERSON∫

TheyPRPO

recommendedVBDO

thatINO

theDTO

drugNNO

''''O

beINO


consideredVBNO

forINO

	treatmentNNO

ofINO

hotJJO

flashesNNSO

inINO

womenNNSO

withINO

breastNNO

cancerNNO
	
..O

''''Oú

Dr.NNPPERSON

PandyaNNPPERSON

	undertookVBDO

thisDTO

studyNNO

afterINO

Dr.NNPPERSON

ThomasNNPPERSON

J.NNPPERSON

GuttusoNNPPERSON

Jr.NNPPERSON
	
,,O


aDTO

neurologistNNO

thenRBO

atINO

theDTO


universityNNO

'sPOSO

medicalJJO

centerNNO
	
,,O

	publishedVBNO

findingsNNSO

inINO

FebruaryNNPO

2003CDO

inINO


ObstetricsNNPORGANIZATION

&CCORGANIZATION


GynecologyNNPORGANIZATION
	
..OçÄÄÄ¯ˇˇˇˇ *ORGANIZATIONéÄÄÄ¯ˇˇˇˇ 
*PERSONèÄÄÄ¯ˇˇˇˇ  *PERSONï

Dr.NNPPERSON

GuttusoNNPPERSON

andCCO

hisPRP$O


colleaguesNNSO

hadVBDO

randomlyRBO

assignedVBNO

59CDO

postmenopausalJJO

womenNNSO

whoWPO

sufferedVBDO

fromINO

sevenCDO

orCCO

moreJJRO

hotJJO

flashesNNSO


aDTO

dayNNO

toTOO

receiveVBO


gabapentinNNO

orCCO


aDTO

placeboNNO

forINO

12CDO

weeksNNSO
	
..OêÄÄÄ¯ˇˇˇˇ  *PERSONÑ

ReducingVBGO

theDTO

HeatNNPO

ThoseDTO

whoWPO

tookVBDO

300CDO


milligramsNNSO

ofINO


gabapentinNNO

threeCDO

timesNNSO


aDTO

dayNNO

reportedVBDO


aDTO

54CDO

percentNNO

	reductionNNO

inINO

overallJJO

hotJJO

flashNNO

activityNNO

-LRB--LRB-O

	frequencyNNO

andCCO

severityNNO

-RRB--RRB-O

comparedVBNO

withINO


aDTO

31CDO

percentNNO

dropNNO

inINO

theDTO

placeboNNO

groupNNO
	
..Oô

InINO

anDTO

	interviewNNO
	
,,O

Dr.NNPPERSON

GuttusoNNPPERSON
	
,,O

nowRBO

atINO

theDTO

JacobsNNPORGANIZATION
!
NeurologicalNNPORGANIZATION

	InstituteNNPORGANIZATION

atINO

theDTO


UniversityNNPORGANIZATION

atINORGANIZATION

BuffaloNNPORGANIZATION
	
,,O

	discussedVBDO


aDTO

soon-to-be-publishedJJO

studyNNO

byINO

Dr.NNPPERSON

SireeshaNNPPERSON

Y.NNPPERSON

ReddyNNPPERSON

andCCO


colleaguesNNSO

thatWDTO

pittedVBDO

2,400CDO


milligramsNNSO

ofINO


gabapentinNNO

dailyRBO

againstINO

0.625CDO

	milligramNNO

ofINO

estrogenNNO
	
,,O

theDTO

goldJJO

standardNNO

forINO

controllingVBGO

hotJJO

flashesNNSO
	
..OëÄÄÄ¯ˇˇˇˇ *PERSONíÄÄÄ¯ˇˇˇˇ *ORGANIZATIONìÄÄÄ¯ˇˇˇˇ
 *ORGANIZATIONîÄÄÄ¯ˇˇˇˇ *PERSONœ

ParticipantsNNSO

sufferedVBDO

fromINO

moderateJJO

toTOO

severeVBO

hotJJO

flashesNNSO
	
,,O

definedVBNO

asINO

sevenCDO

orCCO

moreJJRO

perINO

dayNNO
	
,,O

accompaniedVBNO

byINO

sweatingVBGO
	
..O˘


GabapentinNNPO

relievedVBDO

hotJJO

flashesNNSO

asRBO

effectivelyRBO

asINO

estrogenNNO
	
,,O

Dr.NNPPERSON

GuttusoNNPPERSON

saidVBDO
	
..OïÄÄÄ¯ˇˇˇˇ	 
*PERSON 

AlthoughINO

aboutINO

40CDO

percentNNO

ofINO

theDTO

womenNNSO

takingVBGO

2,400CDO


milligramsNNSO

ofINO


gabapentinNNO

dailyRBO

reportedVBDO

sideNNO

effectsNNSO

-LRB--LRB-O


sleepinessNNO
	
,,O

	dizzinessNNO

andCCO

swellingVBGO

ofINO

theDTO

feetNNSO

-RRB--RRB-O
	
,,O

theyPRPO

feltVBDO

thatINO

theDTO

benefitNNO

ofINO

theDTO

drugNNO


outweighedVBDO

themPRPO
	
,,O

Dr.NNPPERSON

GuttusoNNPPERSON

saidVBDO
	
..OñÄÄÄ¯ˇˇˇˇ& '*PERSONa


GabapentinNNPO

hasVBZO

otherJJO

benefitsNNSO
	
..O

''''O√

ItPRPO

doesVBZO

notRBO

interactVBO

withINO

anyDTO

otherJJO

medicationsNNSO
	
,,O

whichWDTO

isVBZO

veryRBO

uniqueJJO
	
,,O

''''O

Dr.NNPPERSON

GuttosoNNPPERSON

saidVBDO
	
,,O

''''O

soINO

doctorsNNSO

doVBPO

n'tRBO

haveVBO

toTOO

worryVBO

aboutINO

otherJJO

drugsNNSO


aDTO

patientNNO

mightMDO

beVBO

takingVBGO
	
..OóÄÄÄ¯ˇˇˇˇ *PERSONÎ

AlsoRBO
	
,,O


gabapentinNNO

isVBZO

notRBO

metabolizedVBNO
	
,,O

soINO

itPRPO

hasVBZO

noDTO

effectNNO

onINO

theDTO

liverNNO
	
..OÉ

ItPRPO

'sVBZO

fullyRBO

excretedVBNO

inINO

theDTO

urineNNO
	
..O

''''Oô

HePRPO

saidVBDO

thatINO

itPRPO

worksVBZO

throughINO


aDTO

receptorNNO

onINO

theDTO

	membranesNNSO

ofINO

brainNNO

andCCO


peripheralJJO

nerveNNO

cellsNNSO
	
..O—

EstrogenNNO

normallyRBO

actsVBZO

asINO


aDTO

brakeNNO

onINO

cellsNNSO

inINO

theDTO

brainNNO

'sPOSO

temperature-regulatingJJO

centerNNO

throughINO

pathwaysNNSO

calledVBNO

calciumNNO

channelsNNSO
	
..O]


GabapentinNNPO

bindsNNSO

toTOO


aDTO

channelNNO
	
..O«


GabapentinNNPO

wasVBDO

	developedVBNO

toTOO

helpVBO

avoidVBO

theDTO

	addictiveJJO

qualityNNO

ofINO

drugsNNSO

calledVBNO

GABANNPORGANIZATION

analogsNNSO

-LRB--LRB-O

ValiumNNPORGANIZATION
	
,,O

AtivanNNPLOCATION

andCCO

XanaxNNPO

-RRB--RRB-O

usedVBNO

forINO

anxietyNNO

andCCO

seizureNNO

	disordersNNSO
	
..OòÄÄÄ¯ˇˇˇˇ *LOCATIONôÄÄÄ¯ˇˇˇˇ *ORGANIZATIONöÄÄÄ¯ˇˇˇˇ *ORGANIZATIONe

TheDTO

modifiedVBNO

drugNNO

provedVBNO

nonaddictiveJJO
	
..O∫

ProperlyRBO

designedJJO

clinicalJJO

trialsNNSO

areVBPO

neededVBNO

toTOO

showVBO

justRBO

howWRBO

helpfulJJO


gabapentinNNO

isVBZO

againstINO

variousJJO


conditionsNNSO

andCCO

whetherINO

	prolongedVBNO

useNNO

mayMDO

haveVBO


unexpectedJJO

adverseJJO

effectsNNSO
	
..OÀ

AtINO

highJJO

dosesNNSO
	
,,O

sideNNO

effectsNNSO

likeINO


drowsinessNNO
	
,,O

	dizzinessNNO

andCCO

weightNNO

gainNNO

fromINO

retainedJJO

waterNNO

canMDO

limitVBO

itsPRP$O


usefulnessNNO
	
..Oæ

NowRBO

thatINO

theDTO

drugNNO

isVBZO

withoutINO

patentNNO


protectionNNO
	
,,O

futureJJO

F.D.A.NNPO

	approvalsNNSO

willMDO

dependVBO

onINO

studiesNNSO

byINO

twoCDO

	companiesNNSO
	
..OÉ

OneCDO
	
,,O


PharmaNovaNNPORGANIZATION
	
,,O

hasVBZO

patentedVBNO


aDTO

sustained-releaseNNO

formulationNNO

ofINO


gabapentinNNO

andCCO

isVBZO

studyingVBGO

itsPRP$O

roleNNO

inINO

treatingVBGO

hotJJO

flashesNNSO
	
..OõÄÄÄ¯ˇˇˇˇ *ORGANIZATIONç

	MeanwhileRBO
	
,,O

PfizerNNPPERSON

hasVBZO


introducedVBNO


aDTO

chemicalNNO

cousinNNO

ofINO


gabapentinNNO
	
,,O

soldVBNO

asINO

LyricaNNPLOCATION

andCCO

approvedVBNO

forINO

treatingVBGO

nerveNNO

painNNO

causedVBNO

byINO

shinglesNNSO

andCCO

diabetesNNSO
	
..OúÄÄÄ¯ˇˇˇˇ *LOCATION?ùÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f800000000007695b *PERSONv

ItPRPO

shouldMDO

controlVBO

hotJJO

flashesNNSO
	
,,O

tooRBO
	
..O¡

LyricaNNPLOCATION

isVBZO

beingVBGO

studiedVBNO

inINO

patientsNNSO

withINO

hotJJO

flashesNNSO

underINO


aDTO

	licensingNNO

	agreementNNO

withINO

theDTO


UniversityNNPORGANIZATION

ofINORGANIZATION

	RochesterNNPORGANIZATION
	
,,O

whichWDTO

hasVBZO

patentedVBNO

newJJO

usesNNSO

ofINO


gabapentinNNO

andCCO

otherJJO

drugsNNSO

thatWDTO

useVBPO

theDTO

sameJJO

	mechanismNNO
	
..OEûÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f800000000003e9b0 *ORGANIZATIONüÄÄÄ¯ˇˇˇˇ   *LOCATION‡

SomeDTO

FindNNPO

ReliefNNPO

FromINO

theDTO

HeatNNO

byINO

ChangingVBGO

HabitsPRP$O

BecauseINO


gabapentinNNO

andCCO

LyricaNNPLOCATION

areVBPO

alreadyRBO

onINO

theDTO

marketNNO
	
,,O

thereEXO

isVBZO

nothingNNO

toTOO

stopVBO


physiciansNNSO

fromINO

prescribingVBGO

themPRPO

forINO

anyDTO

useNNO
	
,,O

	includingVBGO

hotJJO

flashesNNSO
	
..O†ÄÄÄ¯ˇˇˇˇ *LOCATION≤

ButCCO

herbalJJO

andCCO

nutritionalJJO

remediesNNSO

likeINO

blackJJO

cohoshNNO

andCCO

soyNNO

supplementsNNSO

haveVBPO

notRBO

	withstoodVBNO


controlledJJO

clinicalJJO

trialsNNSO
	
..O≥

HereRBO

areVBPO

someDTO

alternativesNNSO

thatWDTO

mayMDO

reduceVBO

theDTO

	frequencyNNO

andCCO

severityNNO

ofINO

hotJJO

flashesNNSO
	
::O

GettingVBGO

regularJJO

exerciseNNO
	
..OË

AvoidingVBGO

highlyRBO

spicedVBNO

foodsNNSO
	
,,O

largeJJO

mealsNNSO
	
,,O

hotJJO

drinksNNSO
	
,,O

caffeineJJO

andCCO

alcoholNNO
	
..Ou

UsingVBGO

stressNNO

	reductionNNO


techniquesNNSO

likeINO

yogaNNO
	
..Oì

TakingVBGO

lowJJO

dosesNNSO

ofINO

theDTO

antidepressantsNNSO

EffexorNNO
	
,,O

PaxilNNPORGANIZATION

orCCO

ProzacNNPORGANIZATION
	
..O°ÄÄÄ¯ˇˇˇˇ
 
*ORGANIZATION¢ÄÄÄ¯ˇˇˇˇ *ORGANIZATIONL

DrinkingVBGO

lotsNNSO

ofINO

waterNNO
	
..Oœ

WearingVBGO

looseJJO

clothesNNSO

-LRB--LRB-O

noDTO

turtlenecksNNSO

-RRB--RRB-O

inINO

easilyRBO

	removableJJO

layersNNSO
	
..OV

SleepingVBGO

inINO


aDTO

coolJJO

roomNNO
	
..O%

PERSONALNNPO

HEALTHNNO